Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

Progenika to provide blood group genotyping reference laboratory services to ARUP

Progenika to provide blood group genotyping reference laboratory services to ARUP

Celgene announces fiscal 2009 third-quarter results

Celgene announces fiscal 2009 third-quarter results

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

Leading oncology experts to discuss management of hematological malignancies

Leading oncology experts to discuss management of hematological malignancies

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

New study on behaviour of telomeres during cell division in cancerous human cells

New study on behaviour of telomeres during cell division in cancerous human cells

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Association of Specialty Professors announces the 2009 T. Franklin Williams scholars

Association of Specialty Professors announces the 2009 T. Franklin Williams scholars

Innexus Biotechnology announces business development initiative on lead preclinical candidate

Innexus Biotechnology announces business development initiative on lead preclinical candidate

Epigenetic alterations may serve as markers for chronic leukemia

Epigenetic alterations may serve as markers for chronic leukemia

Silenced genes provide warning sign of blood cancer

Silenced genes provide warning sign of blood cancer

Active ingredient in green tea shows promise in leukemia trials

Active ingredient in green tea shows promise in leukemia trials

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.